

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/001241

International filing date: 30 March 2005 (30.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0411688.5
Filing date: 25 May 2004 (25.05.2004)

Date of receipt at the International Bureau: 21 June 2005 (21.06.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

AmBrewes

Dated 14 March 2005



**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference _____

JF/PB60817P1

25 MAY 2004

2. Patent application number

(The Patent Office will fill in his part)

0411688.5

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its corporation.

United Kingdom

47358700 3

4. Title of the invention

Chemical Process

5. Name of your agent (*if you have one*)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (*if you know it*)

8072355006

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months

Country	Priority application number (<i>if you know it</i>)	Date of filing (<i>day / month / year</i>)
---------	--	---

7. Divisionals: etc Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier application	Date of filing (<i>day / month / year</i>)
-------------------------------	---

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Yes

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Otherwise answer NO See note (d)

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document.

Continuation sheets of this form

Description
Claim(s)
Abstract
Drawings

19

3

1

1 Oct 19

2

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

**Statement of inventorship and right
to grant of a patent (*Patents Form 7/77*)**

**Request for preliminary examination
and search (*Patents Form 9/77*)**

Request for substantive examination
(Patents Form 10/77)

**Any other documents
(please specify)**

11. I/We request the grant of a patent on the basis of this application

Signature(s) J. Florence
J. Florence

Date: 25-May-04

12. Name and daytime telephone number of person to contact in the United Kingdom

J Florence 01438 768597

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- Notes**


 - a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505
 - b) Write your answers in capital letters using black ink or you may type them.
 - c) If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
 - d) If you have answered 'Yes' in part 8, a Patents Form 7/77 will need to be filed.
 - e) Once you have filled in the form you must remember to sign and date it.
 - f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6), or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with priority details.

CHEMICAL PROCESS


The present invention relates to the preparation of a β_2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I) defined below. More particularly the invention relates to a process for preparing a crystalline monohydrochloride salt of compound (Ia) defined below.

β_2 Adrenergic receptor agonists are recognized as effective drugs for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (including chronic bronchitis and emphysema). β_2 Adrenergic receptor agonists are also useful for treating premature labour, and are potentially useful for treating neurological disorders and cardiac disorders.

International Patent Application WO 01/42193 and corresponding US Patent No. 6,576,793 disclose *inter alia* a novel compound of the formula (I):



wherein the stereochemistry at *C and **C may be *inter alia* (R) and (R). This compound may be more particularly represented by the formula (Ia):



Compound (Ia) may variously be referred to by the chemical names *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine; *N*-[3-[(1*R*)-1-hydroxy-2-[[2-4-[(2*R*)-2-hydroxy-2-phenylethyl]amino]phenyl]ethyl]amino]ethyl-6-hydroxyphenyl]-formamide and (α -*R*)-3-

formamido-4-hydroxy-(α -[[[p-(N-((2R)-hydroxy-phenethyl))-amino-phenethyl]amino]methyl]benzyl alcohol. In CAS format the compound (la) is designated:


N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[2-4-[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethyl]amino]ethyl]phenyl]-formamide.


5

Compound (la) is a potent β_2 adrenergic receptor agonist.

WO 01/42193 and US Patent No. 6,576,793 describe the preparation of compound (la) as a mixture of stereoisomers, that is, wherein the stereochemistry at *C is (RS) and the 10 stereochemistry at **C is (RS), according to the following reaction scheme:

Scheme 1






5

wherein Bn represents a benzyl protecting group.

US patent application no 10/627,555 and corresponding International published application WO 04/011416 describe the crystalline dihydrochloride salt of compound (la) and methods for preparing said salt. In said applications, compound (la) is prepared according to the following reaction scheme 2:

Scheme 2

In Scheme 2 the abbreviations used have the following meanings:

NaHMDS:	sodium hexamethyldisilazane
THF:	tetrahydrofuran
5 DMPU:	1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)pyrimidinone
TBDMSCl:	tert-butyldimethylsilylchloride
DMF:	dimethylformamide
DMSO:	dimethylsulphoxide
TREAT HF:	triethylamine trihydrofluoride

10 The numbering of compounds in Scheme 2 follows that in WO 04/011416, but it will be appreciated that compound 1 in Scheme 2 is equivalent to compound (Ia) herein.


15 According to WO 04/011416, the dihydrochloride salt of compound 1 is prepared by dissolving compound 1 in a polar solvent to form a first solution and adding hydrochloric acid to form a second solution from which the dihydrochloride salt is formed by crystallisation.

20 We have now found a method for preparing a monohydrochloride salt of compound (I), in particular a monohydrochloride salt of compound (Ia) and most preferably a crystalline monohydrochloride salt of compound (Ia).


It will be appreciated from the foregoing that the compound of formula (I) includes two asymmetric centres, namely at the carbon atoms designated in formula (I) as *C and **C.
25 References herein to compounds of formula (I) include both (S) and (R) enantiomers either in substantially pure form or admixed in any proportions, at both *C and **C. Thus, the stereochemistry at *C and **C may be (RS) and (RS), (R) and (R), (R) and (S), (S) and (R), or (S) and (S).
30 Hereinafter references to compound (I) should be read as including in particular compound (Ia) unless otherwise specified.

Thus, in a first aspect the present invention provides a process for preparing a monohydrochloride salt of compound (I) which process comprises the steps of:

- a) contacting a protected form of compound (I), or compound (Ia) (hereinafter compound (II) and (IIa) respectively):



5



wherein P¹ represents a hydroxyl protecting group, such as benzyl, and P² and P³ each independently represent hydrogen or a hydroxyl protecting group;

10

with a weak acid, eg. acetic acid, to effect selective protonation;

- b) contacting the product of (a) with a source of chloride ions eg. sodium chloride, to effect anion exchange;
- c) deprotecting the product of (b) to remove P¹, and where necessary P² and P³;
- d) isolation of compound (I) or (Ia) as a monohydrochloride salt; and optionally
- e) crystallisation or recrystallisation of compound (I) or (Ia).

Examples of the hydroxyl protecting group P¹ include arylalkyl eg. benzyl. Where either or both of P² and P³ represent protecting groups these may be groups which can be selectively removed under conditions which do not also remove P¹. Thus, each of P² and P³ may be for example a silyl group, eg. a trialkyl silyl group such as tert-butyldimethyl

silyl. In one embodiment of this invention P¹ represents a protecting group and P² and P³ both represent hydrogen.

It will be appreciated by those skilled in the art that compounds (I) and (Ia) contain two basic nitrogen atoms and thus have the potential to form salts at both. In order to obtain a monohydrochloride directly, ie. by reaction of compound (II) or (IIa) with hydrochloric acid, the reaction must be carefully controlled to achieve the correct stoichiometry, and avoid formation of eg. a dihydrochloride salt.

We have found that effecting initial protonation with a weak acid such as acetic acid results in selective protonation of only one nitrogen atom (the more basic nitrogen atom) and, following anion exchange, formation of a stoichiometrically exact monohydrochloride salt. The process of the present invention also has the advantage that the hydrochloride salt can be prepared without the use of strong acid. It is desirable to avoid the use of a strong acid as this can lead to deformylation of the parent compound.


In step (a) of the present process, a compound of formula (II) or (IIa), conveniently in an organic solvent such as 2-butanone (methylethylketone), or diethylketone may be contacted with a weak acid. Weak acids which may be employed include for example acetic acid, 2-methoxybenzoic acid or 4-methoxybenzoic acid. This may conveniently be effected at a slightly elevated temperature, for example at a temperature in the range from about 25°C to about 50°C.

Step (b) may conveniently be effected without isolating the product from step (a). Thus for example the solution obtained from step (a) may be contacted with a source of chloride ions, using eg. aqueous sodium chloride. This step may also conveniently be effected at a temperature in the range from about 25°C to about 50°C. At this stage the intermediate product may be isolated using conventional methods to provide the monohydrochloride salt of compound (II) or (IIa). This product may be obtained in crystalline form.

Deprotection of (II) or (IIa) according to step (c) may be effected by conventional methods. Thus where one or both of P² and P³ represents a silyl group this may be removed for example using cesium fluoride, in an organic solvent such as methanol, optionally in admixture with a further solvent such as diethylketone, methylethylketone or n-butylacetate, or triethylamine trifluoride in a solvent such as tetrahydrofuran. A protecting

group P¹ may be removed for example by hydrogenation using a palladium or platinum catalyst eg. Pd/C, conveniently in an organic solvent such as N-methylpyrrolidone.

- Monohydrochloride salt of compound (I) or (Ia) prepared according to the present invention may be isolated by conventional means. Advantageously said monohydrochloride salt of compound (Ia) may be obtained in crystalline form, by precipitation from an aqueous organic solution. In a particular embodiment crystalline (Ia) monohydrochloride may be obtained from an organic solution comprising a mixture of N-methylpyrrolidone and isopropylalcohol (preferably 1:1), by heating said solution to a temperature in the range from about 60°C to about 80°C, adding water and then contacting the resulting aqueous solution with further isopropylalcohol. During addition of further isopropyl alcohol the temperature is cooled, initially in the range from about 15°C to about 25°C and subsequently in the range from about 0° to about 10°.
- Recrystallisation of monohydrochloride salt of compound (I) or (Ia) may be effected by suspending or dissolving said compound in a suitable solvent, for example industrial methylated spirits, optionally in admixture with water, and initiating crystallisation in conventional manner, eg. with cooling.
- The present invention also provides crystalline (Ia) monohydrochloride (alternatively crystalline *N*-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl) ethylamine monohydrochloride) in a form which is characterised by a differential scanning calorimetry trace which shows an absence of discernable endothermic features below about 125°C, two or more minor endothermic events between about 130 °C and about 180 °C and an onset of significant endothermic heat flow at about 229°C. For example, said minor endothermic events may occur at about 133 °C and at about 151 °C; in addition a further minor endothermic event may occur at about 170 °C.
- The compound of formula (II) or (IIa) wherein P² and P³ both represent hydrogen may be obtained from a corresponding compound of formula (III).




wherein P¹ and P³ are as defined for compound (II) and P^{2'} is a hydroxyl protecting group.
 P^{2'} may be selected from hydroxyl protecting groups known in the art, e.g. a silyl group
 5 such as tert-butyldimethylsilyl. It will be appreciated that P¹, P^{2'} and P³ should be selected
 such that P^{2'} and P³ can be removed under conditions which will not also remove P¹.


When P^{2'} represents a tert-butyldimethylsilyl group this may conveniently be removed
 10 using cesium fluoride, in an organic solvent such as methanol, optionally in admixture with
 a further solvent such as diethylketone, methylethylketone or n-butylacetate.

It will be understood that when it is desired to obtain a compound (Ia) the appropriate
 chiral intermediate is desirably employed in this stage and in the stages described
 hereinafter. Structures (III) (IV) and (V) should therefore be interpreted as depicting the
 15 individual chiral forms as well as mixtures thereof.

A compound (III) may be obtained by reaction of a compound (IV):



20 wherein Hal is a halo leaving group, eg. bromo, and P^{2'} is as defined for formula (III) with a
 compound (V):



wherein P³ is as defined for formula (III).

The reaction of (IV) and (V) may conveniently be effected in the presence of a base, such

5 as potassium carbonate and in a solvent such as N,N-dimethylacetamide.

Compounds (IV) and (V) may be coupled, in a solvent such as N,N-dimethylacetamide or
dimethylsulphoxide, by adding potassium carbonate and sodium hydroxide or sodium
iodide and heating to a temperature in the range of about 90°C to about 140°C to form a

10 compound (III), which may be further reacted without isolation.

The compound (V) may be obtained by coupling 2-(4-aminophenyl)ethylamine and styrene oxide.



15

It will be appreciated that to prepare a compound (Ia), the correct chiral form of compound (V) should be employed. This may be prepared by employing (R)-styrene oxide in the above reaction.

20 The amine, which is optionally provided as a salt, may first be reacted with between about 1 and about 1.2 equivalents of a base having a pK_a value greater than about 18, in order to substantially deprotonate the 4-amino group. The (R)-styrene oxide is added to the product of the amine reaction. Useful basic compounds include sodium bis(trimethylsilyl)amide, alternatively known as sodium hexamethyldisilazane (NaHMDS),
25 lithium diisopropyl amide, and n-butyl lithium. The reaction is preferably conducted in a solvent system including a polar aprotic solvent, such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)pyrimidinone (DMPU). Additional examples of aprotic polar solvents include dimethylsulfoxide, N-methyl pyrrolidinone, N,N-dimethyl acetamide, tetramethylethylenediamine, and hexamethylphosphoramide. After aqueous extraction,
30 the product of the coupling reaction may be crystallized as the hydrochloride salt from a solvent such as isopropanol, by the addition of aqueous hydrochloric acid. The crystallization procedure efficiently separates the desired product from side products

formed during the reaction. The hydrochloride salt may be redissolved with 10 N aqueous sodium hydroxide to provide 2-[4-((R)-2-hydroxy-2-phenylethylamino) phenyl]ethylamine (compound (V)).

- 5 The corresponding (S) stereoisomer, 2-[4-((S)-2-hydroxy-2-phenylethylamino)phenyl]ethylamine, can be prepared by substituting (S)-styrene oxide for (R)-styrene oxide in the above procedure for the synthesis of compound (V).

Compounds of formula (IV) may be prepared by methods known in the art. Thus for example a compound of formula (IV) wherein P² is hydrogen may be prepared as described in US Patent No. 6,268,533 B1; and in R. Hett et al., Organic Process Research and Development, 1998, 2, 96-99, or using procedures similar to those described by Hong et al., Tetrahedron Ltt., 1994, 35, 6631; or similar to those described in US Patent No. 5,495,054. A protecting group P² may be introduced by standard methods, for example by the addition of tert-butyldimethylsilylchloride (TBDMS-Cl) and dissolved in a suitable solvent such as dichloromethane.

Brief description of the drawings

- 20 Figure 1 shows an x-ray powder diffraction pattern of *N*-{2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(R)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride (Compound (Ia) monohydrochloride).

For a better understanding of the invention, the following Examples are given by way of illustration.

LCMS analysis was conducted on a Phenomenex Luna C18(2) column (50 mm x 2.0 mm ID, 3um), eluting with 0.05%v/v trifluoroacetic acid in water (solvent A), and 0.05%v/v trifluoroacetic acid in acetonitrile (solvent B). An elution gradient of 0% solvent B to 95% solvent B over 8 minutes at a flow rate of 1.0 ml/min was used. The mass spectra were recorded on a Micromass Q-ToF spectrometer using electrospray positive mode (ES+ve).

XRPD analysis shown in Figure 1 was performed on a Bruker X-ray powder diffractometer, Model D8 Advance, serial number ROE 2357. The method runs from 2 to 40 degrees 2-Theta with a 0.0145 degree 2-Theta step size and a 1 second collection time at each step.

The differential scanning calorimetry analysis was obtained with a Perkin Elmer instrument model Pyris 1. Samples were weighed into a 50 microlitre aluminium pan, an aluminium lid placed on top of the sample and compressed with a brass rod. An aluminium cover was placed on top of the pan and sealed using a universal press. An 5 empty pan, lid and cover serving as a reference. Samples were equilibrated at 30 °C and heated at 10 °C per minute to a temperature of 300 °C. The instrument was calibrated using indium, tin and lead standards.

10

Abbreviations

TBDMS-Cl: *tert*-butyldimethylsilyl chloride

DCM: dichloromethane

DMA: *N,N*-dimethylacetamide

15 MEK: 2-Butanone (methylethyl ketone)

NMP: N-methylpyrrolidone

IPA: Isopropylalcohol

IMS: industrial methylated spirit (in the following examples composition of IMS was Ethanol -96%, methanol 4%)

20

Reference Examples

a) Synthesis of 2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethylamine (2)

To a 1000 mL 3-neck flask was added 10 g (74 mmol) of 2-(4-aminophenyl)ethylamine 25 and 15 mL of 1,3-dimethyl-3,4,5,6-tetrahydro- 2(1*H*)pyrimdinone (DMPU). The reaction flask was fitted with an overhead stirrer, a 125 mL addition funnel and a thermometer. The reaction flask was purged with nitrogen and placed in a cold water bath. The addition funnel was charged with 83 mL (83 mmol) of 1.0 M sodium bis(trimethylsilyl)amide in tetrahydrofuran. The sodium bis(trimethylsilyl)amide solution was added dropwise over 30 30 min with vigorous stirring. The addition funnel was removed and replaced with a rubber septum. (*R*)-styrene oxide (8.4 mL, 74 mmol) was added dropwise by syringe over 10 minutes. The rate of addition was controlled to maintain a temperature below 35° C. After 1 h, the reaction was quenched by dropwise addition of 88 mL water. The reaction mixture was transferred to a separatory funnel, diluted with 56 mL isopropyl acetate and 35 washed with 84 mL saturated aqueous sodium chloride. The organic layer was washed a second time with a mixture of 84 mL water and 84 mL saturated aqueous sodium chloride

and finally with 84 mL saturated aqueous sodium chloride. The organic layer was concentrated under vacuum. The residue was twice reconcentrated from isopropanol (55 mL portions) and then redissolved in isopropanol (235 mL) and heated to 70°C with stirring. Concentrated hydrochloric acid (13.2 mL, 160 mmol) was added over two minutes. The mixture was allowed to cool to room temperature and stirred for 14 h. The precipitated product was isolated by filtration and washed with isopropanol and isopropyl acetate. The product was dried under vacuum for 3 h and then dissolved in 56 mL water and transferred to a separatory funnel. Isopropyl acetate (56 mL) and 10 N aqueous sodium hydroxide (19 mL, 190 mmol) were added. The separatory funnel was shaken and the phases separated. The organic layer was dried over sodium sulfate and concentrated to afford the product (2) as an orange-brown oil (11 g, 44 mmol, 59%). *m/z*: [M + H⁺] calcd for C₁₆H₂₀N₂O 257.2; found 257.2.

b) Synthesis of 2-bromo-(*R*)-1-*tert*-butyldimethylsiloxy-1-(3-formamido-4-benzyloxyphenyl)ethane (4)

(*R*)-2-Bromo-1-(3-formamido-4-benzyloxyphenyl)ethanol (intermediate 3) (9.9 g, 28 mmol) was dissolved in 36 mL dimethylformarnide. Imidazole (2.3 g, 34 mmol) and *t*-butyldimethylsilylchloride (4.7 g, 31 mmol) were added. The solution was stirred under nitrogen atmosphere for 72 h. Additional imidazole (0.39 g, 5.7 mmol) and *t*-butyldimethylsilylchloride (0.64 g, 4.3 mmol) were added and the reaction was stirred for an additional 20 h. The reaction was diluted with a mixture of isopropyl acetate (53 mL) and hexanes (27 mL) and transferred to a separatory funnel. The organic layer was twice washed with a mixture of water (27 mL) and saturated aqueous sodium chloride (27 mL) followed by a final wash with saturated aqueous sodium chloride (27 mL). The organic layer was dried over sodium sulfate. Silica gel (23.6 g) and hexanes (27 mL) were added and the suspension was stirred for 10 minutes. The solids were removed by filtration and the filtrate concentrated under vacuum. The residue was crystallized from hexanes (45 mL) to afford 8.85 g (19 mmol, 68 %) of intermediate 4 as a white solid. *m/z*: [M + H⁺] calcd for C₂₂H₃₀NO₃SiBr 464.1, 466.1; found 464.2, 466.4.

c) Synthesis of *N*-(2-[4((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl)(*R*)-2-*tert*-butyldimethylsiloxy-2-(3-formamido-4- benzyloxyphenyl)ethylamine (5)

Intermediate 4 (5.0 g, 11 mmol), intermediate 2 (3.5 g, 14 mmol), and dimethylsulfoxide (10 mL) were combined in a 100 mL round bottom flask and stirred to form a homogeneous solution. Potassium carbonate (6.0 g, 43 mmol) and sodium iodide (1.7 g, 11 mmol) were added and the reaction mixture was heated to 140°C. The reaction

mixture was maintained at 140°C for 10 min, then cooled to room temperature and diluted with water (24 mL) and isopropyl acetate (28 mL). The reaction was stirred until all solids dissolved and then transferred to a separatory funnel. The organic layer was washed with water (17 mL) followed by acetate buffer (5% v/v acetic acid, 12% w/v sodium acetate trihydrate in water, 18 mL) followed by sodium bicarbonate solution (5% w/v in water, 17 mL) followed by saturated aqueous sodium chloride (17 mL). The organic layer was dried over sodium sulfate and concentrated to afford intermediate 5 as a brown gelatinous solid (7.0g, 11 mmol, >99%). *m/z*: [M + H⁺] calcd for C₃₈H₄₉N₃O₄Si 640.4; found 640.6.

10 d) **Synthesis of N-[2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl]-(*R*)-2-hydroxy-2-(3-formamido-4-benzyloxyphenyl)ethylamine (6)**

Intermediate 5 (5.2 g, 8.1 mmol) was dissolved in tetrahydrofuran (26 mL) and triethylamine trihydrofluoride (1.4 mL, 8.6 mmol) was added. The solution was stirred for 20 h. The reaction was quenched by addition of water (7.6 mL) followed by 10.0 N sodium hydroxide (3.8 mL, 38 mmol). After 3 min, the reaction was diluted with isopropyl acetate (20 mL) and transferred to a separatory funnel. The mixture was shaken and the biphasic mixture was filtered through celite to remove undissolved solids. The filtrate was returned to a separatory funnel and the phases were separated. The organic layer was washed with a mixture of 9 mL water and 9 mL saturated aqueous sodium chloride followed by 15 mL of saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate and concentrated to afford the product 6 as a brown gelatinous solid (4.2 g, 8.0 mmol, 99%). *m/z*: [M + H⁺] calcd for C₃₂H₃₅N₃O₄ 526.3; found 526.4.

25 e) **Synthesis of N-[2-[4-((R)-2-hydroxy-2-phenylethylamino)phenyl]ethyl]-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine (1)**

Intermediate 6 (2.5 g, 4.8 mmol) was dissolved in 8.0 mL of ethanol and treated with activated charcoal, Darco G-60 (1.25 g). The suspension was stirred at 50°C for 20 min and then filtered to remove the Darco. To the filtrate was added 10% palladium on activated carbon (250 mg) and the suspension placed on a Parr shaker. The reaction was shaken for 10 h under 30 psi hydrogen gas. The reaction was filtered through celite and concentrated under vacuum to afford compound 1 as a brown gelatinous solid (1.9 g, 4.3 mmol, 91%). ¹HNMR (300 MHz, DMSO-d₆) δ 2.40-2.68 (m, 6H), 2.92-3.18 (m, 2H), 4.35-4.45 (m, 1H), 4.60-4.69 (m, 1H), 5.22-5.30 (m, 1H), 6.82 (s, 1H), 6.85 (s, 1H), 6.68-6.86 (m, 4H), 7.12-7.36 (m, 5H), 7.95 (d, 1H, *J*= 1.4 Hz), 8.19 (s, 1H), 9.49 (br s, 1H). *m/z*: [M + H⁺] calcd for C₂₅H₂₉N₃O₄ 436.2; found 436.4.

f) Crystallization of *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine monohydrochloride

In a 500 mL round bottom flask, compound **1** (5.2 g, 11.9 mmol) was dissolved in 187.9 mL isopropyl alcohol with stirring at 40°C. Complete dissolution was achieved within 10 minutes. The flask was then charged with a solution containing 1.0 N HCl (11.3 mL, 11.3 mmol, 0.95 eq.) and H₂O (29.6 mL). The solution was stirred and the product crystallized over several hours. After 6h, the crystals were isolated by filtration and washed with 15 mL ice-cold 15% water in isopropyl alcohol solution followed by 15 mL of isopropyl alcohol. The crystals were dried under house vacuum for 12-16 h to afford the monohydrochloride salt of compound **1** (3.92 g, 8.3 mmol, 70% yield, 98.89% purity by HPLC) as a white crystalline solid. Water content 0.2 %, ¹H NMR (300 MHz, DMSO-d₆): δ (ppm) 10.13 (s, 1H), 9.62 (m, 1H), 8.93 (br s, 1H), 8.66 (br s, 1H), 8.27 (d, 1H, J=1.92), 8.13 (d, 1H, J=1.65), 7.21-7.40 (m, 5H), 6.86-6.94 (m, 4H), 6.57 (d, 2H, J=8.52), 6.05 (d, 1H, J=3.57), 5.45-5.55 (m, 2H), 4.80 (m, 1H), 4.70 (m, 1H), 2.70-3.24 (m, 8H). Elemental analysis (wt %) calcd for C₂₅H₂₉N₃O₄.HCl: C, 63.62; H, 6.41; N, 8.90; Cl, 7.51. found: C, 63.47; H, 6.54; N, 8.81; Cl, 7.78.

Example 1

i) 2-Bromo-(*R*)-1-*tert*-butyldimethylsiloxy-1-(3-formamido-4-benzyloxyphenyl)ethane
A solution of TBDMS-Cl (40.1 g, 0.26 mol) in DCM (37.5 mL) was added to a slurry of imidazole (21.86 g, 0.32 mol) and (*R*)-2-bromo-1-(3-formamido-4-benzyloxyphenyl)ethanol (74.54 g, 0.21 mol) in DCM (260 mL) over 8 minutes. The mixture was stirred for 22 hours. The reaction was quenched with water (190 mL) and the aqueous layer was extracted with DCM (37.5 mL). The combined DCM layers were distilled at atmospheric pressure to a volume of ca. 110 mL. On cooling, spontaneous crystallisation occurred. Isooctane (750 mL) was added dropwise over 20 minutes. The slurry was cooled to 0 °C and the solids were collected by filtration then washed with 9:1 v/v isooctane:DCM (3 x 75 mL) and dried *in vacuo* to give the *title compound* as a colourless solid (89.65 g, 90% th). ¹H NMR in accord with structure (400 MHz, CDCl₃) δ(ppm): -0.06 (3H) s; 0.11(3H) s; *0.12 (3H) s; *0.89 (9H) s; 0.90 (9H) s; *3.38-3.49 (2H) m; 4.78-4.87 (1H) m; *5.09 (2H) s; 5.10 (2H) s; 6.96 (1H) d, J=8.6Hz; *7.06 (1H) d of d, J=8.3, 2.0Hz; 7.11 (1H) d of d, J=8.3Hz, 2.0Hz; 7.25-7.27 (1H) m; 7.36-7.45 (5H) m; *7.70 (1H) d, J=11.0Hz; 7.79 (1H) s; 8.38 (1H) d, J=2.0Hz; 8.42 (1H) d, J=1.5Hz; *8.76 (1H) d, J=11.8Hz.

* Peaks are due to ca 25M% of the minor rotamer.

5 ii) ***N*{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-benzyloxyphenyl) ethylamine monohydrochloride**

2-[4-((*R*)-2-Hydroxy-2-phenylethylamino) phenyl]ethylamine (19.8 g, 60 mmol) was dissolved in water (80 mL). Isopropyl acetate (100 mL) was added with stirring. 32% w/v aqueous sodium hydroxide solution (17.2 mL) was added with stirring over 8 minutes.

10 The organic layer was washed with water (100 mL) then distilled at atmospheric pressure to a volume of ca. 70 mL.

To this solution was added DMA (50 mL) followed by 2-bromo-(*R*)-1-*tert*-butyldimethylsiloxy-1-(3-formamido-4-benzyloxyphenyl)ethane (20 g, 43 mmol) and potassium carbonate (7.44 g, 54 mmol). The mixture was heated at 90 °C (oil bath

15 temperature) for 17 hours then cooled to 50 °C. Water (150 mL) was added and the mixture was cooled further to room temperature. MEK (150 mL) was added and the layers were separated. The organic layer was washed with 17:40:340 v/w/v acetic acid:sodium acetate:water (100 mL) followed by 29% w/v aqueous sodium chloride solution (100 mL). The organic layer was diluted with MEK (50 mL) and then distilled at

20 atmospheric pressure to a volume of ca 150 mL. More MEK (50 mL) was added followed by a solution of cesium fluoride (8.1 g, 51.6 mmol) in methanol (100 mL). The mixture was heated at 37 °C for 7.5 hours then cooled to 30 °C. The reaction was quenched with 44% w/v aqueous potassium carbonate solution (100 mL) and water (20 mL) was added. The organic layer was washed with 29% w/v aqueous sodium chloride solution (100 mL)

25 then treated with acetic acid (3.7 mL, 64.6 mmol). The mixture was washed with 29% w/v aqueous sodium chloride solution (100 mL) followed by 6% w/v aqueous sodium chloride solution (3 x 100 mL).

The solution was diluted with MEK (100 mL) then distilled to a volume of ca 120 mL. MEK (80 mL) was added and the mixture was seeded (seeds may be obtained as described in

30 Example 2). The mixture was distilled again to a volume of ca. 140 mL. More MEK (60 mL) was added and the mixture was cooled to room temperature. The solids were collected by filtration, washed with MEK (3 x 20 mL) and dried *in vacuo* to give the *title compound* as a colourless solid (18.64 g, 77%th). ¹H NMR in accord of structure (400 MHz, DMSO-d₆) δ(ppm): 2.70-2.89 (2H) m; 2.95 (1H) m; 3.01-3.14 (4H) m; 3.14-3.23 (1H) m; 4.71 (1H) m; 4.81 (1H) m; *5.17 (1H) s; 5.23 (1H) s; 5.46 (1H) d, J=4.4Hz; 5.50 (1H) m;

6.10 (1H) d, J=3.2Hz; 6.59 (2H) d, J=8.3Hz; 6.94 (2H) d, J=8.3Hz; 7.03 (1H) d of d, J=8.6, 2.0Hz; 7.12 (1H) d, J=8.6Hz; 7.25 (1H) m; 7.30-7.36 (3H) m; 7.36-7.42 (4H) m; 7.50 (2H) d, J=7.3Hz; 8.26 (1H) d, J=2.0Hz; 8.35 (1H) d, J=1.7Hz; *8.54(1H) d, J=11.0Hz; 8.63 (2H) broad res; *9.64 (1H) m; 9.67 (1H) s.

5

* Peaks are due to ca 11.5M% of the minor rotamer.

iii) *N*{2-[4-((*R*)-2-Hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl) ethylamine monohydrochloride

A mixture of *N*{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-benzyloxyphenyl) ethylamine monohydrochloride (40g) and 5% Pd/C catalyst (Englehard 167, 50% wet with water) (200mg) in NMP (120ml) was stirred under hydrogen at 22±2°C. The mixture was filtered (Whatman GF/F filter) when analysis, by hplc (detection at 220nm), of the reaction mixture showed <0.5% (by area) of the starting material (product of Ex 1ii). The filter cake was washed with a mixture of NMP and IPA (1:1) (80ml).

The combined filtrates were stirred and heated to 69±3°C. Water (10ml) was added. IPA (100ml) was added at a rate that maintained the temperature at 69±3°C. Seed crystals (0.8g) were added. IPA (50ml) was added over 15minutes. The resulting mixture was stirred for about 0.75h. IPA (250ml) was then added over about 2.5h. The resulting slurry was allowed to cool slowly to 20±3°C and stirred at this temperature for ca 16h.

The resulting slurry was cooled to 3±3°C and stirred at this temperature for 4h. The slurry was filtered and the collected solid was washed successively with IPA/water (10:1) (80ml) and IPA (160ml). The solid was dried under vacuum at ca 50°C to give the *title compound* as a white solid (29.7g).

Yield: 88%th, 74%w/w

NMR: δ(ppm): 2.73-2.89 (2H) m; 2.95 (1H) m; 3.01-3.14 (4H) m; 3.15-3.24 (1H) m; 4.72 (1H) m; 4.82 (1H) m; 5.46 (1H) d, J = 4.7Hz; 5.48 (1H) m; 6.03 (1H) d, J=3.4Hz; 6.59 (2H) d, J=8.6Hz; 6.89 (1H) d, J=8.1Hz; 6.91-6.98 (3H) m; *7.01 (1H) d, J=8.6Hz; *7.14 (1H) s; 7.25 (1H) t, J=7.3Hz; 7.33 (2H) t, J=7.3, 7.6Hz; 7.39 (2H)

d, J=7.6Hz; 8.13 (1H) d, J=1.5Hz; 8.29 (1H) d, J=1.7Hz; *8.53 (1H) d, J=11.0Hz; 8.57-9.08 (2H) broad res; *9.36 (1H) d, J=11.0Hz; 9.60 (1H) s; *9.92 (1H) s; 10.10 (1H) s.

- 5 * Peaks are due to ca 11M% of the minor rotamer.

iv) **Recrystallisation of *N*{2-[4-((*R*)-2-Hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl) ethylamine monohydrochloride**

10 The title monohydrochloride (5g) was suspended in aqueous industrial methylated spirit (IMS) (2:1 IMS:water, 72.5ml) in a 100ml round bottomed flask. The mixture was warmed to 78°C to give a clear solution. This was filtered, washed through with aqueous IMS (2:1 IMS:water, 2.5ml) and the liquor rewarmed to 78°C to re-dissolve the solid that precipitated during the filtration. The temperature was adjusted to 65°C and seeded with 15 monohydrochloride (10mg). The mixture was held at 60-65°C for 2 hours and then cooled to 20-25°C and stirred at that temperature for 14 hours. The suspension was chilled to 0-5°C and held at that temperature for 3 hours. The product was collected via filtration, and washed with aqueous IMS (2:1 IMS: water, 2 X 7.5ml) and then IMS (3 X 7.5ml) to give the *title compound* as a white solid, which was dried at 50°C under vacuum overnight.

20

Expected yield: 80%th, 80%w/w

The XRPD pattern of this product is shown in Figure 1.

25 The differential scanning calorimetry trace for this product shows an absence of discernable endothermic features below about 125°C, with minor endothermic events having onsets at about 133 °C, about 151 °C and at about 170 °C.

30 **Example 2**


***N*{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-benzyloxyphenyl) ethylamine monohydrochloride**

35 *N*{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-benzyloxyphenyl) ethylamine (96.1 mg, 0.18 mmol) was dissolved in 2-propanol (2.2 mL)

with warming. A solution of hydrochloric acid in dioxane (4 M, 45 μ L, 0.18 mmol) was added. At the end of the addition the majority of material was present as a gum which was stirred at room temperature overnight. The solids were collected by filtration, washed with 2-propanol (3 x 1 mL) and dried by suction on the filter to give the *title compound* as a colourless solid (69.5 mg, 69%). ^1H NMR in accord with structure (400 MHz, DMSO-d₆,).

CLAIMS

1. A process for preparing a monohydrochloride salt of compound (I)




5

wherein *C and **C denote asymmetric carbon atoms,
which process comprises the steps of:

a) contacting a compound of formula (II):

10



wherein P¹ represents a hydroxyl protecting group, and P² and P³ each independently represents hydrogen or a protecting group;


15

with a weak acid, to effect selective protonation;

20


- b) contacting the product of (a) with a source of chloride ions, to effect anion exchange;
- c) deprotection to remove P¹, and where necessary P² and P³;
- d) isolation of compound (I) as the monohydrochloride; and optionally
- e) crystallisation or recrystallisation of compound (I).

2. A process according to claim 1, wherein the compound of formula (I) is the compound (Ia):



5

and the compound of formula (II) is the compound (IIa):



10 wherein P^1 is as defined in claim 1.

3. A process according to claim 1 or claim 2 wherein the weak acid is acetic acid.
- 15 4. A process according to any of claims 1 to 3 wherein the group P^1 represents benzyl.
5. A process according to any of claims 1 to 4 wherein the source of chloride ions is sodium chloride.
- 20 6. A process according to any of claims 1 to 5 for the preparation of a crystalline monohydrochloride salt of the compound of formula (Ia).
7. A process according to claim 6 wherein the product of said process is characterised by an x-ray powder diffraction pattern in which the peak positions are substantially in accordance with the peak positions of the pattern shown in Fig. 1.
- 25

8. Crystalline (Ia) monohydrochloride which is characterised by a differential scanning calorimetry trace which shows an absence of discernable endothermic features below about 125°C.
5
9. Crystalline (Ia) monohydrochloride which is characterised by a differential scanning calorimetry trace which shows an absence of discernable endothermic features below about 125°C, and an onset of significant endothermic
10 heat flow at about 229°C.
10. Crystalline (Ia) monohydrochloride which is characterised by a differential scanning calorimetry trace which shows an absence of discernable endothermic features below about 125°C, two or more minor endothermic events
15 between about 130°C and about 180°C and an onset of significant endothermic heat flow at about 229°C.
11. Crystalline (Ia) monohydrochloride according to claim 10 wherein
20 said minor endothermic events occur at about 133°C, at about 151°C and at about 170°C.



Figure 1

